Dulac Edward J III 4
4 · Intellia Therapeutics, Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Dulac Edward J III
EVP, Chief Financial Officer
Transactions
- Award
Common Stock
2025-03-01+47,200→ 113,524 total - Award
Stock Option (right to buy)
2025-03-01+67,429→ 67,429 totalExercise: $10.09Exp: 2035-02-28→ Common Stock (67,429 underlying)
Footnotes (2)
- [F1]Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
- [F2]This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.